



General Meeting and Board of Directors of December 12, 2019

Paris, France. December 12, 2019 –10.00 PM CET– Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, held its General Meeting today in Paris, which adopted all the proposed resolutions.

The General Meeting has, in particular, approved the proposed transfer of listing to Euronext Growth Paris. The transfer is still subject to approval by Euronext Paris SA.

The General Meeting has also ratified the appointment of Mr. Lloyd Diamond, Chief Executive Officer, and Sofinnova Partners as Directors.

The Board of Directors of Pixium Vision is composed of the following members:

- Mr Bernard Gilly, Chairman of the Board
- Mr Lloyd Diamond, Chief Executive Officer and Director
- BPIfrance Participations, represented by Mrs Olivia Le Proux de la Rivière, Director
- Sofinnova Partners, represented by Mr Gérard Hascoët, Director
- Mrs Marie Meynadier, Independent Director
- Robert J. W. Ten Hoedt, Independent Director

- Kreos Capital V (Expert Fund) LTD, represented by Mr Aris Constantidines, Observer

The General Meeting also approved the authorization that will enable the Board of Directors, after the transfer of listing to Euronext Growth Paris, to draw down the 2nd tranche of the convertible bond granted by European Select Growth Opportunities Fund, which may represent up to €8,750,000, in the form of free warrants giving access to ORNAN2019 (bonds redeemable in cash or convertible into new shares).

Contacts

Pixium Vision

Didier Laurens
Chief Financial Officer
investors@pixium-vision.com
+33 1 76 21 47 68

Media relations

LifeSci Advisors
Sophie Baumont
sophie@lifesciadvisors.com
+33 6 27 74 74 49

Investor relation

LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 62 54

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information :  <http://www.pixium-vision.com/fr>

Follow us on  @PixiumVision;  www.facebook.com/pixiumvision

Linkedin  www.linkedin.com/company/pixium-vision

PIX
LISTED
EURONEXT



Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext CAC All Shares index

Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg:PIX:FP